Crossmark

Teverelix is a potential treatment option for the prevention of acute urinary retention recurrence in men suffering from benign prostatic hyperplasia

Published Online: 2024-10-20

Authors

Ulys, Albertas https://orcid.org/0000-0002-3465-3558
Černiauskienė, Aušra https://orcid.org/0000-0003-2251-411X
Geavlete, Petrișor https://orcid.org/0000-0001-7276-8308
Larsen, Finn

MacLean, Carol M. https://orcid.org/0000-0002-2948-3734
van Os, Steve
License Information

Text and Data Mining valid from 2024-10-20

Version of Record valid from 2024-10-20
More Information

Article History

Received: 17 September 2024

Accepted: 5 October 2024

First Online: 20 October 2024

Declarations

:

: The authors declare that there are no competing interests.

Document is current